Analysts expect Puma Biotechnology Inc (NASDAQ:PBYI) to announce earnings per share (EPS) of ($0.75) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Puma Biotechnology’s earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.64). Puma Biotechnology reported earnings of ($1.16) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 35.3%. The business is scheduled to issue its next quarterly earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Puma Biotechnology will report full-year earnings of ($4.07) per share for the current year, with EPS estimates ranging from ($4.33) to ($3.72). For the next fiscal year, analysts forecast that the company will report earnings of $0.18 per share, with EPS estimates ranging from ($0.93) to $0.92. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to analysts’ expectations of $20.83 million. During the same quarter in the previous year, the business earned ($1.22) earnings per share.
In related news, SVP Richard Paul Bryce sold 1,860 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the sale, the senior vice president now directly owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Alan H. Auerbach sold 10,692 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the sale, the insider now directly owns 4,155,931 shares in the company, valued at $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of PBYI. Parametric Portfolio Associates LLC grew its holdings in Puma Biotechnology by 13.5% in the second quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 936 shares during the period. Nationwide Fund Advisors grew its holdings in Puma Biotechnology by 22.5% in the third quarter. Nationwide Fund Advisors now owns 19,879 shares of the biopharmaceutical company’s stock valued at $2,381,000 after purchasing an additional 3,657 shares during the period. First Trust Advisors LP acquired a new stake in Puma Biotechnology in the third quarter valued at approximately $549,000. American Century Companies Inc. grew its holdings in Puma Biotechnology by 17.9% in the third quarter. American Century Companies Inc. now owns 51,984 shares of the biopharmaceutical company’s stock valued at $6,225,000 after purchasing an additional 7,882 shares during the period. Finally, Sei Investments Co. acquired a new stake in Puma Biotechnology in the third quarter valued at approximately $256,000. 95.95% of the stock is currently owned by institutional investors.
Shares of Puma Biotechnology stock traded down $1.25 during trading hours on Thursday, hitting $71.20. The stock had a trading volume of 517,885 shares, compared to its average volume of 1,043,928. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90. The stock has a market capitalization of $2,687.53, a PE ratio of -9.07 and a beta of 0.26. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.79 and a current ratio of 1.82.
ILLEGAL ACTIVITY NOTICE: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3290093/puma-biotechnology-inc-pbyi-expected-to-announce-earnings-of-0-75-per-share.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.